The Cooper Companies, Inc. $COO Shares Purchased by Evelyn Partners Investment Management LLP

Evelyn Partners Investment Management LLP grew its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 196.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,935 shares of the medical device company’s stock after purchasing an additional 2,608 shares during the quarter. Evelyn Partners Investment Management LLP’s holdings in Cooper Companies were worth $280,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Zions Bancorporation National Association UT purchased a new position in shares of Cooper Companies during the first quarter valued at approximately $33,000. J.Safra Asset Management Corp raised its holdings in Cooper Companies by 204.8% in the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 340 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in shares of Cooper Companies during the 1st quarter worth $40,000. Assetmark Inc. boosted its holdings in shares of Cooper Companies by 357.8% during the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock worth $44,000 after purchasing an additional 483 shares during the last quarter. Finally, Allworth Financial LP grew its position in shares of Cooper Companies by 36.6% in the second quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after purchasing an additional 257 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Trading Up 6.1%

NASDAQ COO opened at $75.47 on Friday. The firm has a market capitalization of $15.00 billion, a price-to-earnings ratio of 37.18, a PEG ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $106.63. The company’s 50 day moving average price is $70.15 and its 200 day moving average price is $71.98.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the firm earned $0.96 earnings per share. Cooper Companies’s revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, sell-side analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its board has authorized a share buyback program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Transactions at Cooper Companies

In related news, CEO Albert G. White III bought 10,000 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was bought at an average price of $68.39 per share, with a total value of $683,900.00. Following the completion of the transaction, the chief executive officer directly owned 226,151 shares of the company’s stock, valued at approximately $15,466,466.89. This represents a 4.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius bought 2,000 shares of the stock in a transaction dated Monday, September 29th. The stock was bought at an average price of $68.39 per share, with a total value of $136,780.00. Following the purchase, the director owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. This represents a 52.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 17,975 shares of company stock worth $1,216,346 in the last quarter. 1.98% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on COO shares. The Goldman Sachs Group set a $64.00 target price on Cooper Companies and gave the stock a “sell” rating in a research report on Wednesday, October 1st. Morgan Stanley set a $76.00 price objective on shares of Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, August 28th. Piper Sandler lowered their target price on shares of Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a report on Thursday, August 28th. JPMorgan Chase & Co. dropped their price target on shares of Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a research report on Thursday, August 28th. Finally, Stifel Nicolaus cut their price target on shares of Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.